Cargando…

Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents

BACKGROUND: Nitrogen heterocyclic rings and sulfonamides have attracted attention of several researchers. RESULTS: A series of regioselective imidazole-based mono- and bis-1,4-disubstituted-1,2,3-triazole-sulfonamide conjugates 4a–f and 6a–f were designed and synthesized. The first step in the synth...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-blewi, Fawzia Faleh, Almehmadi, Meshal A., Aouad, Mohamed Reda, Bardaweel, Sanaa K., Sahu, Pramod K., Messali, Mouslim, Rezki, Nadjet, El Ashry, El Sayed H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768023/
https://www.ncbi.nlm.nih.gov/pubmed/30387018
http://dx.doi.org/10.1186/s13065-018-0479-1
_version_ 1783455040852197376
author Al-blewi, Fawzia Faleh
Almehmadi, Meshal A.
Aouad, Mohamed Reda
Bardaweel, Sanaa K.
Sahu, Pramod K.
Messali, Mouslim
Rezki, Nadjet
El Ashry, El Sayed H.
author_facet Al-blewi, Fawzia Faleh
Almehmadi, Meshal A.
Aouad, Mohamed Reda
Bardaweel, Sanaa K.
Sahu, Pramod K.
Messali, Mouslim
Rezki, Nadjet
El Ashry, El Sayed H.
author_sort Al-blewi, Fawzia Faleh
collection PubMed
description BACKGROUND: Nitrogen heterocyclic rings and sulfonamides have attracted attention of several researchers. RESULTS: A series of regioselective imidazole-based mono- and bis-1,4-disubstituted-1,2,3-triazole-sulfonamide conjugates 4a–f and 6a–f were designed and synthesized. The first step in the synthesis was a regioselective propargylation in the presence of the appropriate basic catalyst (Et(3)N and/or K(2)CO(3)) to afford the corresponding mono-2 and bis-propargylated imidazoles 5. Second, the ligation of the terminal C≡C bond of mono-2 and/or bis alkynes 5 to the azide building blocks of sulfa drugs 3a–f using optimized conditions for a Huisgen copper (I)-catalysed 1,3-dipolar cycloaddition reaction yielded targeted 1,2,3-triazole hybrids 4a–f and 6a–f. The newly synthesized compounds were screened for their in vitro antimicrobial and antiproliferative activities. Among the synthesized compounds, compound 6a emerged as the most potent antimicrobial agent with MIC values ranging between 32 and 64 µg/mL. All synthesized molecules were evaluated against three aggressive human cancer cell lines, PC-3, HepG2, and HEK293, and revealed sufficient antiproliferative activities with IC(50) values in the micromolar range (55–106 μM). Furthermore, we conducted a receptor-based electrostatic analysis of their electronic, steric and hydrophobic properties, and the results were in good agreement with the experimental results. In silico  ADMET prediction studies also supported the experimental biological results and indicated that all compounds are nonmutagenic and noncarcinogenic. CONCLUSION: In summary, we have successfully synthesized novel targeted benzimidazole-1,2,3-triazole-sulfonamide hybrids through 1,3-dipolar cycloaddition reactions between the mono- or bis-alkynes based on imidazole and the appropriate sulfonamide azide under the optimized Cu(I) click conditions. The structures of newly synthesized sulfonamide hybrids were confirmed by means of spectroscopic analysis. All newly synthesized compounds were evaluated for their antimicrobial and antiproliferative activities. Our results showed that the benzimidazole-1,2,3-triazole-sulfonamide hybrids inhibited microbial and fungal strains within MIC values from 32 to 64 μg/mL. The antiproliferative evaluation of the synthesized compounds showed sufficient antiproliferative activities with IC(50) values in the micromolar range (55–106 μM). In conclusion, compound 6a has remarkable antimicrobial activity. Pharmacophore elucidation of the compounds was performed based on in silico ADMET evaluation of the tested compounds. Screening results of drug-likeness rules showed that all compounds follow the accepted rules, meet the criteria of drug-likeness and follow Lipinski’s rule of five. In addition, the toxicity results showed that all compounds are nonmutagenic and noncarcinogenic. [Image: see text]
format Online
Article
Text
id pubmed-6768023
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-67680232019-10-03 Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents Al-blewi, Fawzia Faleh Almehmadi, Meshal A. Aouad, Mohamed Reda Bardaweel, Sanaa K. Sahu, Pramod K. Messali, Mouslim Rezki, Nadjet El Ashry, El Sayed H. Chem Cent J Research Article BACKGROUND: Nitrogen heterocyclic rings and sulfonamides have attracted attention of several researchers. RESULTS: A series of regioselective imidazole-based mono- and bis-1,4-disubstituted-1,2,3-triazole-sulfonamide conjugates 4a–f and 6a–f were designed and synthesized. The first step in the synthesis was a regioselective propargylation in the presence of the appropriate basic catalyst (Et(3)N and/or K(2)CO(3)) to afford the corresponding mono-2 and bis-propargylated imidazoles 5. Second, the ligation of the terminal C≡C bond of mono-2 and/or bis alkynes 5 to the azide building blocks of sulfa drugs 3a–f using optimized conditions for a Huisgen copper (I)-catalysed 1,3-dipolar cycloaddition reaction yielded targeted 1,2,3-triazole hybrids 4a–f and 6a–f. The newly synthesized compounds were screened for their in vitro antimicrobial and antiproliferative activities. Among the synthesized compounds, compound 6a emerged as the most potent antimicrobial agent with MIC values ranging between 32 and 64 µg/mL. All synthesized molecules were evaluated against three aggressive human cancer cell lines, PC-3, HepG2, and HEK293, and revealed sufficient antiproliferative activities with IC(50) values in the micromolar range (55–106 μM). Furthermore, we conducted a receptor-based electrostatic analysis of their electronic, steric and hydrophobic properties, and the results were in good agreement with the experimental results. In silico  ADMET prediction studies also supported the experimental biological results and indicated that all compounds are nonmutagenic and noncarcinogenic. CONCLUSION: In summary, we have successfully synthesized novel targeted benzimidazole-1,2,3-triazole-sulfonamide hybrids through 1,3-dipolar cycloaddition reactions between the mono- or bis-alkynes based on imidazole and the appropriate sulfonamide azide under the optimized Cu(I) click conditions. The structures of newly synthesized sulfonamide hybrids were confirmed by means of spectroscopic analysis. All newly synthesized compounds were evaluated for their antimicrobial and antiproliferative activities. Our results showed that the benzimidazole-1,2,3-triazole-sulfonamide hybrids inhibited microbial and fungal strains within MIC values from 32 to 64 μg/mL. The antiproliferative evaluation of the synthesized compounds showed sufficient antiproliferative activities with IC(50) values in the micromolar range (55–106 μM). In conclusion, compound 6a has remarkable antimicrobial activity. Pharmacophore elucidation of the compounds was performed based on in silico ADMET evaluation of the tested compounds. Screening results of drug-likeness rules showed that all compounds follow the accepted rules, meet the criteria of drug-likeness and follow Lipinski’s rule of five. In addition, the toxicity results showed that all compounds are nonmutagenic and noncarcinogenic. [Image: see text] Springer International Publishing 2018-11-01 /pmc/articles/PMC6768023/ /pubmed/30387018 http://dx.doi.org/10.1186/s13065-018-0479-1 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Al-blewi, Fawzia Faleh
Almehmadi, Meshal A.
Aouad, Mohamed Reda
Bardaweel, Sanaa K.
Sahu, Pramod K.
Messali, Mouslim
Rezki, Nadjet
El Ashry, El Sayed H.
Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents
title Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents
title_full Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents
title_fullStr Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents
title_full_unstemmed Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents
title_short Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents
title_sort design, synthesis, adme prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768023/
https://www.ncbi.nlm.nih.gov/pubmed/30387018
http://dx.doi.org/10.1186/s13065-018-0479-1
work_keys_str_mv AT alblewifawziafaleh designsynthesisadmepredictionandpharmacologicalevaluationofnovelbenzimidazole123triazolesulfonamidehybridsasantimicrobialandantiproliferativeagents
AT almehmadimeshala designsynthesisadmepredictionandpharmacologicalevaluationofnovelbenzimidazole123triazolesulfonamidehybridsasantimicrobialandantiproliferativeagents
AT aouadmohamedreda designsynthesisadmepredictionandpharmacologicalevaluationofnovelbenzimidazole123triazolesulfonamidehybridsasantimicrobialandantiproliferativeagents
AT bardaweelsanaak designsynthesisadmepredictionandpharmacologicalevaluationofnovelbenzimidazole123triazolesulfonamidehybridsasantimicrobialandantiproliferativeagents
AT sahupramodk designsynthesisadmepredictionandpharmacologicalevaluationofnovelbenzimidazole123triazolesulfonamidehybridsasantimicrobialandantiproliferativeagents
AT messalimouslim designsynthesisadmepredictionandpharmacologicalevaluationofnovelbenzimidazole123triazolesulfonamidehybridsasantimicrobialandantiproliferativeagents
AT rezkinadjet designsynthesisadmepredictionandpharmacologicalevaluationofnovelbenzimidazole123triazolesulfonamidehybridsasantimicrobialandantiproliferativeagents
AT elashryelsayedh designsynthesisadmepredictionandpharmacologicalevaluationofnovelbenzimidazole123triazolesulfonamidehybridsasantimicrobialandantiproliferativeagents